TNF regulates essential alternative complement pathway components and impairs activation of protein C in human glomerular endothelial cells

Journal of Immunology

Volumn 196, Issue 2, 2016, Pages 832-845

  Sartain, Sarah E ^a,b   Turner, Nancy A ^c   Moake, Joel L ^c  

^a Texas Children's Cancer and Hematology Centers   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; INTERLEUKIN 1BETA; MEMBRANE COFACTOR PROTEIN; PROTEIN C; THROMBOMODULIN; TUMOR NECROSIS FACTOR; LEUKOCYTE ANTIGEN; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; ARTICLE; C3 GENE; CAPILLARY ENDOTHELIAL CELL; CFB GENE; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; KIDNEY FAILURE; PRIORITY JOURNAL; THBD GENE; BIOSYNTHESIS; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULUS; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT PATHWAY, ALTERNATIVE; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOASSAY; KIDNEY GLOMERULUS; MICROSCOPY, FLUORESCENCE; PROTEIN C; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954137061     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500960     Document Type: Article

References (63)

1. Benz, K., and K. Amann. 2009. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS)/thrombocytic thrombopenic purpura (TTP). Thromb. Haemost. 101: 265-270.
2. Noris, M., and G. Remuzzi. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361: 1676-1687.
3. Ruggenenti, P., M. Noris, and G. Remuzzi. 2001. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60: 831-846.
4. Caprioli, J., F. Castelletti, S. Bucchioni, P. Bettinaglio, E. Bresin, G. Pianetti, S. Gamba, S. Brioschi, E. Daina, G. Remuzzi, and M. Noris, International Registry of Recurrent and Familial HUS/TTP. 2003. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 12: 3385-3395.
5. Pérez-Caballero, D., C. González-Rubio, M. E. Gallardo, M. Vera, M. López-Trascasa, S. Rodríguez de Córdoba, and P. Sánchez-Corral. 2001. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 68: 478-484.
6. Fremeaux-Bacchi, V., M. A. Dragon-Durey, J. Blouin, C. Vigneau, D. Kuypers, B. Boudailliez, C. Loirat, E. Rondeau, and W. H. Fridman. 2004. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 41: e84.
7. Kavanagh, D., A. Richards, M. Noris, R. Hauhart, M. K. Liszewski, D. Karpman, J. A. Goodship, V. Fremeaux-Bacchi, G. Remuzzi, T. H. Goodship and J. P. Atkinson. 2008. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol. Immunol. 45: 95-105.
8. Fremeaux-Bacchi, V., E. A. Moulton, D. Kavanagh, M. A. Dragon-Durey, J. Blouin, A. Caudy, N. Arzouk, R. Cleper, M. Francois, G. Guest, et al. 2006. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 17: 2017-2025.
9. Richards, A., M. Kathryn Liszewski, D. Kavanagh, C. J. Fang, E. Moulton, V. Fremeaux-Bacchi, G. Remuzzi, M. Noris, T. H. Goodship, and J. P. Atkinson. 2007. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol. Immunol. 44: 111-122.
10. Delvaeye, M., M. Noris, A. De Vriese, C. T. Esmon, N. L. Esmon, G. Ferrell, J. Del-Favero, S. Plaisance, B. Claes, D. Lambrechts, et al. 2009. Thrombo-modulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361: 345-357.
11. Frémeaux-Bacchi, V., E. C. Miller, M. K. Liszewski, L. Strain, J. Blouin, A. L. Brown, N. Moghal, B. S. Kaplan, R. A. Weiss, K. Lhotta, et al. 2008. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952.
12. Goicoechea de Jorge, E., C. L. Harris, J. Esparza-Gordillo, L. Carreras, E. A. Arranz, C. A. Garrido, M. López-Trascasa, P. Sánchez-Corral, B. P. Morgan, and S. Rodŕiguez de Córdoba. 2007. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. USA 104: 240-245.
13. Law, S. K., and R. P. Levine. 1977. Interaction between the third complement protein and cell surface macromolecules. Proc. Natl. Acad. Sci. USA 74: 2701-2705.
14. Pangburn, M. K., V. P. Ferreira, and C. Cortes. 2008. Discrimination between host and pathogens by the complement system. Vaccine 26(Suppl. 8): I15-I21.
15. Law, S. K., and A. W. Dodds. 2008. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6: 263-274.
16. Schreiber, R. D., M. K. Pangburn, P. H. Lesavre, and H. J. Müller-Eberhard. 1978. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. USA 75: 3948-3952.
17. Rawal, N., and M. Pangburn. 2001. Formation of high-affinity C5 convertases of the alternative pathway of complement. J. Immunol. 166: 2635-2642.
18. Fearon, D. T., K. F. Austen, and S. Ruddy. 1973. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 138: 1305-1313.
19. Pillemer, L., L. Blum, I. H. Lepow, O. A. Ross, E. W. Todd, and A. C. Wardlaw. 1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120: 279-285.
20. Weiler, J. M., M. R. Daha, K. F. Austen, and D. T. Fearon. 1976. Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl. Acad. Sci. USA 73: 3268-3272.
21. Kinoshita, T., Y. Takata, H. Kozono, J. Takeda, K. S. Hong, and K. Inoue. 1988. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J. Immunol. 141: 3895-3901.
22. Kazatchkine, M. D., D. T. Fearon, and K. F. Austen. 1979. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J. Immunol. 122: 75-81.
23. Whaley, K., and S. Ruddy. 1976. Modulation of the alternative complement pathways by beta 1 H globulin. J. Exp. Med. 144: 1147-1163.
24. Harrison, R. A., and P. J. Lachmann. 1980. The physiological breakdown of the third component of human complement. Mol. Immunol. 17: 9-20.
25. Liszewski, M. K., T. W. Post, and J. P. Atkinson. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9: 431-455.
26. Esmon, C. T., and W. G. Owen. 1981. Identification of an endothelial cell co-factor for thrombin-catalyzed activation of protein C. Proc. Natl. Acad. Sci. USA 78: 2249-2252.
27. Fearon, D. T. 1979. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl. Acad. Sci. USA 76: 5867-5871.
28. Fearon, D. T. 1980. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 152: 20-30.
29. Stearns-Kurosawa, D. J., S. Kurosawa, J. S. Mollica, G. L. Ferrell, and C. T. Esmon. 1996. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA 93: 10212-10216.
30. Nicholson-Weller, A., J. Burge, D. T. Fearon, P. F. Weller, and K. F. Austen. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129: 184-189.
31. Meri, S., B. P. Morgan, A. Davies, R. H. Daniels, M. G. Olavesen, H. Waldmann, and P. J. Lachmann. 1990. Human protectin (CD59), an 18, 000-20, 000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1-9.
32. Feng, S., X. Liang, M. A. Cruz, H. Vu, Z. Zhou, N. Pemmaraju, J. F. Dong, M. H. Kroll, and V. Afshar-Kharghan. 2013. The interaction between factor H and Von Willebrand factor. PLoS One 8: e73715.
33. Tati, R., A. C. Kristoffersson, A. L. Stahl, J. Rebetz, L. Wang, C. Licht, D. Motto, and D. Karpman. 2013. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J. Immunol. 191: 2184-2193.
34. Turner, N. A., and J. Moake. 2013. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Wille-brand factor links complement and hemostasis-thrombosis. PLoS One 8: e59372.
35. Fakhouri, F., Y. Delmas, F. Provot, C. Barbet, A. Karras, R. Makdassi, C. Courivaud, K. Rifard, A. Servais, C. Allard, et al. 2014. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am. J. Kidney Dis. 63: 40-48.
36. Loirat, C., and V. Frémeaux-Bacchi. 2011. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 6: 60.
37. Nolasco, L. H., N. A. Turner, A. Bernardo, Z. Tao, T. G. Cleary, J. F. Dong, and J. L. Moake. 2005. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 106: 4199-4209.
38. Christiansen, D., J. Milland, B. R. Thorley, I. F. McKenzie, P. L. Mottram, L. J. Purcell, and B. E. Loveland. 1996. Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunology 87: 348-354.
39. Qu, Z., X. Liang, Y. Liu, J. Du, S. Liu, and W. Sun. 2009. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through down-regulating CD59. Mol. Immunol. 47: 283-289.
40. Hindmarsh, E. J., and R. M. Marks. 1998. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur. J. Immunol. 28: 1052-1062.
41. Kawakami, Y., Y. Watanabe, M. Yamaguchi, H. Sakaguchi, I. Kono, and A. Ueki. 1997. TNF - A stimulates the biosynthesis of complement C3 and factor B by human umbilical cord vein endothelial cells. Cancer Lett. 116: 21-26.
42. Nan, B., P. Lin, A. B. Lumsden, Q. Yao, and C. Chen. 2005. Effects of TNF - A and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb. Res. 115: 417-426.
43. T) method. Methods 25: 402-408.
44. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 29: e45.
45. Kagawa, H., and S. Fujimoto. 1987. Electron-microscopic and immunocyto-chemical analyses of Weibel-Palade bodies in the human umbilical vein during pregnancy. Cell Tissue Res. 249: 557-563.
46. Turner, N. A., L. Nolasco, Z. M. Ruggeri, and J. L. Moake. 2009. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 114: 5102-5111.
47. Moutabarrik, A., I. Nakanishi, M. Namiki, T. Hara, M. Matsumoto, M. Ishibashi, A. Okuyama, D. Zaid, and T. Seya. 1993. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55 (DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res. 12: 167-172.
48. Conway, E. M., and R. D. Rosenberg. 1988. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell. Biol. 8: 5588-5592.
49. Mackay, F., H. Loetscher, D. Stueber, G. Gehr, and W. Lesslauer. 1993. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 177: 1277-1286.
50. Okuda, K., R. Sakumoto, Y. Uenoyama, B. Berisha, A. Miyamoto, and D. Schams. 1999. Tumor necrosis factor a receptors in microvascular endothelial cells from bovine corpus luteum. Biol. Reprod. 61: 1017-1022.
51. Lee, S. K., S. H. Yang, I. Kwon, O. H. Lee, and J. H. Heo. 2014. Role of tumour necrosis factor receptor-1 and nuclear factor-kB in production of TNF-a-induced pro-inflammatory microparticles in endothelial cells. Thromb. Haemost. 112: 580-588.
52. Bernardo, A., C. Ball, L. Nolasco, J. F. Moake, and J. F. Dong. 2004. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104: 100-106.
53. Foreman, K. E., A. A. Vaporciyan, B. K. Bonish, M. L. Jones, K. J. Johnson, M. M. Glovsky, S. M. Eddy, and P. A. Ward. 1994. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94: 1147-1155.
54. Ikeda, K., K. Nagasawa, T. Horiuchi, T. Tsuru, H. Nishizaka, and Y. Niho. 1997. C5a induces tissue factor activity on endothelial cells. Thromb. Haemost. 77: 394-398.
55. Lundberg, C., F. Marceau, R. Huey, and T. E. Hugli. 1986. Anaphylatoxin C5a fails to promote prostacyclin release in cultured endothelial cells from human umbilical veins. Immunopharmacology 12: 135-143.
56. Schraufstatter, I. U., K. Trieu, L. Sikora, P. Sriramarao, and R. DiScipio. 2002. Complement C3a and C5a induce different signal transduction cascades in en-dothelial cells. J. Immunol. 169: 2102-2110.
57. Hamuro, J., U. Hadding, and D. Bitter-Suermann. 1978. Fragments Ba and Bb derived from guinea pig factor B of the properdin system: purification, characterization, and biologic activities. J. Immunol. 120: 438-444.
58. Kolb, W. P., P. R. Morrow, and J. D. Tamerius. 1989. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm. 6: 175-204.
59. Lesavre, P. H., T. E. Hugli, A. F. Esser, and H. J. Müller-Eberhard. 1979. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 123: 529-534.
60. Maga, T. K., C. J. Nishimura, A. E. Weaver, K. L. Frees, and R. J. H. Smith. 2010. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum. Mutat. 31: E1445-E1460.
61. Noris, M., J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, S. Gamba, E. Daina, C. Fenili, F. Castelletti, A. Sorosina, et al. 2010. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5: 1844-1859.
62. Thieme, T. R., S. H. Hefeneider, C. R. Wagner, and D. R. Burger. 1987. Recombinant murine and human IL 1 alpha bind to human endothelial cells with an equal affinity, but have an unequal ability to induce endothelial cell adherence of lymphocytes. J. Immunol. 139: 1173-1178.
63. Thieme, T. R., and C. R. Wagner. 1989. The molecular weight of the endothelial cell IL-1 receptor is 78, 000. Mol. Immunol. 26: 249-253.